Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26203726 | 0.83 | CES2 (0.36) | GABRA1GABRB1CES2CES1CA1 | |
| SCHEMBL30014342 | 0.83 | PDE2A (0.35) | — | |
| SCHEMBL23526123 | 0.83 | PDE2A (0.35) | — | |
| SCHEMBL23526125 | 0.83 | PDE2A (0.35) | — | |
| SCHEMBL9821046 | 0.83 | CES2 (0.33) | GABRA1GABRB1CES2CES1 | |
| SCHEMBL29325148 | 0.80 | GABRA1 (0.35) | GABRA1GABRB1 | |
| SCHEMBL25839065 | 0.80 | GABRA1 (0.35) | GABRA1GABRB1 | |
| SCHEMBL23063467 | 0.78 | GABRA1 (0.54) | GABRA1GABRB1CA1CA2 | |
| SCHEMBL20609888 | 0.78 | GAA (0.36) | GABRA1GABRB1CA1CA2 | |
| SCHEMBL31376150 | 0.78 | GABRA1 (0.34) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | GABRA1 3962/4885GABRB1 3361/4885CES2 4258/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | GABRA1 3926/4885GABRB1 3516/4885CES2 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.